Update on FDA approval of XIPERE for macular edema associated with uveitis from Bausch + Lomb
Bausch + Lomb's Yolande Barnard shares an update on the FDA approval of XIPERE for the treatment of macular edema associated with uveitis.
Modern Retina™'s David Hutton speaks with Yolande Barnard, vice president and general manager, U.S. Pharmaceuticals, Bausch + Lomb, on the company's latest FDA approval of XIPERE (triamcinolone acetonide injectable suspension) for the treatment of macular edema associated with uveitis.
XIPERE is the first—and currently only— FDA-approved therapy utilizing suprachoridal administration.
The American Academy of Ophthalmology (AAO) annual meeting was held November 12 to 15 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The event included Subspecialty Days and a virtual component for remote participation.
Related Content: Additional AAO Content | Ophthalmology | Conference Coverage
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
